Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
1.970
+0.310 (18.67%)
At close: Nov 20, 2026, 4:00 PM EST
1.940
-0.030 (-1.52%)
After-hours: Nov 20, 2026, 7:57 PM EST
Insight Molecular Diagnostics Employees
As of December 31, 2025, Insight Molecular Diagnostics had 58 total employees, including 55 full-time and 3 part-time employees. The number of employees increased by 9 or 18.37% compared to the previous year. That makes Insight Molecular Diagnostics the 34,311th largest employer in the world and 4,536th in the United States.
Employees
58
Change (1Y)
9
Growth (1Y)
18.37%
Revenue / Employee
$33,948
Profits / Employee
-$725,586
Market Cap
64.47M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 58 | 9 | 18.37% | 55 | 3 |
| Dec 31, 2024 | 49 | 3 | 6.52% | 46 | 3 |
| Dec 31, 2023 | 46 | -30 | -39.47% | 43 | 3 |
| Dec 31, 2022 | 76 | -39 | -33.91% | 75 | 1 |
| Dec 31, 2021 | 115 | 64 | 125.49% | 110 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| Fulgent Genetics | 1,315 |
| Burning Rock Biotech | 667 |
| MDxHealth | 364 |
| Biodesix | 334 |
| XWELL | 280 |
| Exagen | 220 |
| Precipio | 71 |
IMDX News
- 2 days ago - Insight Molecular price target lowered to $9 from $12 at Lake Street - TheFly
- 2 days ago - Insight Molecular enrolls first patients in GALACTIC registry study - TheFly
- 2 days ago - iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study - GlobeNewsWire
- 5 days ago - Insight Molecular Diagnostics 8.3M share Spot Secondary priced at $1.75 - TheFly
- 5 days ago - Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering - GlobeNewsWire
- 5 days ago - Insight Molecular price target lowered to $4 from $8 at Lucid Capital - TheFly
- 5 days ago - Insight Molecular Diagnostics reports Q3 EPS (10c), two estimates (22c) - TheFly
- 5 days ago - Insight Molecular Diagnostics Earnings Call Transcript: Q3 2026 - Transcripts